Elicera Therapeutics AB (publ) (STO:ELIC)
Sweden · Delayed Price · Currency is SEK 3.340
+0.180 (5.70%)
Apr 30, 2026, 12:52 PM CET
Elicera Therapeutics AB Revenue
Elicera Therapeutics AB had revenue of 10.64M SEK in the twelve months ending March 31, 2026, up 146.66% year-over-year. In the year 2025, Elicera Therapeutics AB had annual revenue of 10.86M with 52.28% growth.
Revenue (ttm)
10.64M
Revenue Growth
+146.66%
P/S Ratio
14.42
Revenue / Employee
3.55M
Employees
2
Market Cap
153.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.86M | 3.73M | 52.28% |
| Dec 31, 2024 | 7.13M | -4.10M | -36.52% |
| Dec 31, 2023 | 11.23M | 9.95M | 777.23% |
| Dec 31, 2022 | 1.28M | 1.28M | 217,987.39% |
| Dec 31, 2021 | 587.00 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xbrane Biopharma AB | 152.35M |
| IRLAB Therapeutics AB | 57.46M |
| NextCell Pharma AB | 9.83M |
| Xintela AB | 2.28M |
| Alligator Bioscience AB | 839.00K |
| Diamyd Medical AB | 362.00K |
Elicera Therapeutics AB News
- 1 year ago - Elicera Therapeutics AB Transcript: Investor Update - Transcripts